DEF: SI-BONE Invites Stockholders to 2026 Annual Meeting

SI-BONE, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, highlighting significant 2025 financial and operational achievements.

Summary

• SI-BONE, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 4, 2026, at 8:00 a.m. Pacific Time.
• The meeting will cover proposals including the election of two directors, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• The company reported strong performance in 2025, with worldwide revenue reaching $200.9 million, a ~20% increase year-over-year.
• Over 2,400 U.S. physicians performed nearly 22,000 procedures in 2025, bringing the total worldwide procedures to over 140,000 since inception.
• The net loss for 2025 was $18.9 million, an improvement of ~39% compared to the previous year.
• Adjusted EBITDA turned positive at $8.9 million in 2025, a significant improvement from a loss of $5.1 million in 2024.
• The company ended 2025 with $147.8 million in cash and equivalents.
• Key product launches in 2025 included iFuse TORQ across Europe and the granting of a New Technology Add-On Payment for iFuse TORQ TNT procedures.
• The proxy statement details executive compensation, corporate governance practices, and security ownership information.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, improved profitability metrics (positive Adjusted EBITDA), and a solid cash position, indicating sound operational and financial management.

Positives

• Achieved worldwide revenue of $200.9 million in 2025, a ~20% annual increase.
• Performed nearly 22,000 procedures with over 2,400 U.S. physicians in 2025.
• Exceeded 140,000 total procedures performed worldwide since inception.
• Reduced net loss by ~39% to $18.9 million in 2025.
• Achieved positive Adjusted EBITDA of $8.9 million in 2025, compared to a loss of $5.1 million in 2024.
• Ended 2025 with a strong balance sheet, holding $147.8 million in cash and equivalents.
• Successfully launched iFuse TORQ across Europe.
• Secured a New Technology Add-On Payment effective October 1, 2025, for eligible iFuse TORQ TNT inpatient procedures.

Negatives

• The company reported a net loss of $18.9 million for the fiscal year ended December 31, 2025, despite the improvement.
• While Adjusted EBITDA was positive, the company still incurred a net loss.

Risks

• The company's ability to continue to grow its core business through physician training and education.
• Potential for future accounting restatements that could trigger clawback provisions on incentive compensation.
• The effectiveness of cybersecurity measures in protecting IT systems and long-term value.
• The potential for future changes in reimbursement policies or regulatory environments affecting product adoption and revenue.

Future Outlook

The company highlights its progress in 2025, including revenue growth, increased procedures, reduced net loss, positive Adjusted EBITDA, and strategic product launches, suggesting a positive trajectory. The annual meeting agenda focuses on board composition, auditor ratification, and executive compensation, indicating a focus on governance and continued operational execution.

Management Comments

• "We made significant and measurable progress during 2025, including the following: Achieved worldwide revenue of $200.9 million, representing an annual increase of ~20%; Over 2,400 U.S. physicians performed nearly 22,000 procedures; Surpassed 140,000 procedures performed by physicians worldwide since inception; Net loss of $18.9 million, representing an annual improvement of ~39%; Delivered positive Adjusted EBITDA of $8.9 million, as compared to a loss of $5.1 million in 2024; Exited the year with a solid balance sheet with $147.8 million in cash and equivalents; Launched iFuse TORQ across Europe; and Granted New Technology Add-On Payment effective October 1, 2025, providing incremental reimbursement to hospitals for eligible inpatient procedures using iFuse TORQ TNT."
• "I continue to be humbled by the exceptional performance of the entire SI-BONE team, working diligently to introduce new products and continuing to train and educate physicians to grow our core business."
• "Your vote is very important to us, and I urge you to vote your shares as promptly as possible."

Industry Context

StockSavvy.ai notes that SI-BONE's performance in 2025, particularly its revenue growth and positive Adjusted EBITDA, aligns with a recovery trend in the medical device sector, especially for companies focused on minimally invasive procedures. The successful launch of iFuse TORQ in Europe and the new reimbursement for iFuse TORQ TNT indicate strategic expansion and market penetration efforts that are crucial for sustained growth in this competitive industry.

Comparison to Industry Standards

• SI-BONE's revenue growth of ~20% in 2025 is strong compared to the broader medical device industry average, which has seen more moderate growth in recent periods.
• The transition to positive Adjusted EBITDA from a loss is a significant achievement, indicating improved operational efficiency and profitability, a key benchmark for companies in the medical technology space.
• The company's focus on minimally invasive SIJ dysfunction treatment places it in a specialized segment of the orthopedic market. Competitors in this niche include companies developing alternative surgical and non-surgical treatments for back pain.
• The reported cash and equivalents of $147.8 million provide a solid liquidity position, which is generally considered healthy for a company of SI-BONE's size and stage, allowing for continued investment in R&D and market expansion.

Management Changes

Corporate Governance

Legal Proceedings

• One Form 4 was inadvertently filed late by Jeffrey W. Dunn due to an administrative oversight, reporting an option exercise, same day sale and 10b5-1 trading plan sale on December 8, 2025. All other Section 16(a) filing requirements for the fiscal year ended December 31, 2025, were met and made timely.

Related Party Transactions

• No transactions, arrangements, or relationships exceeding $120,000 between the company and a related person have occurred or are proposed since the beginning of the fiscal year ended December 31, 2025.

Stakeholder Impact

• Shareholders: The positive financial results and strategic initiatives are expected to benefit shareholders through potential stock value appreciation and continued company growth. The proxy materials provide shareholders with the opportunity to vote on key governance matters.
• Employees: The company's focus on growth and innovation, coupled with its compensation policies, aims to attract and retain talent. The mention of employee engagement metrics in bonus plans suggests employee well-being is considered.
• Healthcare Professionals: The continued performance and product development (e.g., iFuse TORQ TNT) directly impact the tools and procedures available to physicians, potentially improving patient outcomes.
• Hospitals: The New Technology Add-On Payment for iFuse TORQ TNT procedures provides incremental reimbursement, positively impacting hospital finances for eligible procedures.

Next Steps

• Stockholders are urged to vote their shares for the Annual Meeting.
• The company will hold its Annual Meeting virtually on June 4, 2026.
• Final voting results will be published in a Form 8-K within four business days after the Annual Meeting.

Key Dates

Recommendation

The filing shows strong operational and financial improvements, including significant revenue growth and a move to positive Adjusted EBITDA. However, the company still operates at a net loss, and while the outlook is positive, it warrants a 'hold' recommendation pending sustained profitability and continued execution against strategic goals. The upcoming annual meeting focuses on governance, which is standard for this type of filing.

Keywords

SI-BONE, Proxy Statement, Annual Meeting, Stockholders, Director Election, Executive Compensation, Auditor Ratification, Medical Device, SIJ Dysfunction, iFuse TORQ, Financial Results, SEC Filing